June 18, 2025 10:06 AM EDTUpdated 10:40 AM
News Briefing

Bavar­i­an Nordic's PRV goes for $160M; Bio­mea to ad­vance GLP-1 in­to tri­als

ENDPOINTS

Plus, news about Ca­mu­rus and Pelage Phar­ma­ceu­ti­cals:

Bavar­i­an Nordic to sell its pri­or­i­ty re­view vouch­er: The Dan­ish phar­ma com­pa­ny will

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Grail shares jump on study re­sults for can­cer test

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

Zealand study shows high­er GLP-1/GLP-2 dos­es may lead to greater weight loss

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times